to the oxime 1720 in 88% overall yield. Due to its relative
instability, it was immediately hydrogenated in the presence of
Boc2O; the resulting unstable carbamate carboxylic acid was
methylated to give 18 in 81% overall yield. The appended
acetonide, silyl and t-butoxycarbonyl groups are plausible
factors for the instability of all the carboxylic acid derivatives,
due to their acidic lability. The acidic hydrolysis of 18 followed by
the chemoselective oxidation of the primary hydroxyl group of the
generated diol gave the stable carboxylic acid 19 in 95% overall
yield, which was confirmed downstream upon its conversion to the
corresponding known methyl ester 20.7d It is noted that under
identical deprotection conditions, only the acetonide group was
removed from 13, whereas both the acetonide and silyl groups were
removed from 18. Finally, the global acidic deprotection of 19
produced the dysiherbaine hydrochloride 1ꢁ2HCl quantitatively,
which was briefly treated with aqueous NaOH and then purified on
an ion exchange resin to afford (ꢀ)-dysiherbaine 1 in 95% yield.
Other significant operations in the synthetic sequence include
Stille coupling of 8 and 10, the stereoselective mercuriocyclization
of 2, and the successful epoxidation of the unreactive alkene 12.
This research was supported by the NRF grant funded by
the MEST (2012-0000912 and 2012-0000098). We thank Prof.
David G. Churchill at KAIST for his assistance during the
preparation of this manuscript.
Notes and references
1 R. Sakai, H. Kamiya, M. Murata and K. Shimamoto, J. Am.
Chem. Soc., 1997, 119, 4112.
2 R. Sakai, K. Yoshida, A. Kimura, K. Koike, M. Jimbo, K. Koike,
A. Kobiyama and H. Kamiya, ChemBioChem, 2008, 9, 543.
3 (a) R. Dingledine, K. Borges, D. Bowie and S. F. Trynelis, Pharmacol.
Rev., 1999, 51, 7; (b) D. R. Madden, Nat. Rev. Neurosci., 2002, 3, 91;
(c) G. T. Swanson, T. Green, R. Sakai, A. Contractor, W. Che,
H. Kamiya and S. F. Heinemann, Neuron, 2002, 34, 589; (d) M. L.
Mayer, Curr. Opin. Neurobiol., 2005, 15, 282; (e) J. M. Sanders, K. Ito,
L. Settimo, O. T. Pentikainen, M. Shoji, M. Sasaki, M. S. Johnson,
R. Sakai and G. T. Swanson, J. Pharmacol. Exp. Ther., 2005, 314, 1068;
(f) M. L. Mayer, Nature, 2006, 440, 456.
4 J. M. Sanders, O. T. Pentikainen, L. Settimo, U. Pentikainen,
M. Shoji, M. Sasaki, R. Sakai, M. S. Johnson and G. T. Swanson,
Mol. Pharmacol., 2006, 69, 1849.
5 R. Sakai, G. T. Swanson, M. Sasaki, K. Shimamoto and
H. Kamiya, Cent. Nerv. Syst. Agents Med. Chem., 2006, 6, 83.
6 R. Sakai, G. T. Swanson, K. Shimamoto, A. Contractor,
A. Ghetti, Y. Tamura-Horikawa, C. Oiwa and H. Kamiya,
J. Pharmacol. Exp. Ther., 2001, 296, 650.
7 Total syntheses: (a) B. B. Snider and N. A. Hawryluk, Org. Lett.,
2000, 2, 635; (b) M. Sasaki, T. Koike, R. Sakai and K. Tachibana,
Tetrahedron Lett., 2000, 41, 3923; (c) H. Masaki, J. Maeyama,
K. Kamada, T. Esumi, Y. Iwabuchi and S. Hatakeyama, J. Am.
Chem. Soc., 2000, 122, 5216; (d) D. Phillips and A. R. Chamberlin,
J. Org. Chem., 2002, 67, 3194; (e) M. Sasaki, N. Akiyama,
K. Tsubone, M. Shoji, M. Oikawa and R. Sakai, Tetrahedron Lett.,
2007, 48, 5697; (f) K. Takahashi, T. Matsumura, J. Ishihara and
S. Hatakeyama, Chem. Commun., 2007, 4158; (g) M. Sasaki,
K. Tsubone, K. Aoki, N. Akiyama, M. Shoji, M. Oikawa,
R. Sakai and K. Shimamoto, J. Org. Chem., 2008, 73, 264.
8 Formal and partial syntheses: (a) T. Naito, J. S. Nair, A. Nishiki,
K. Yamashita and T. Kiguchi, Heterocycles, 2000, 53, 2611;
(b) S. H. Kang and Y. M. Lee, Synlett, 2003, 993; (c) O. Miyata,
R. Iba, J. Hashimoto and T. Naito, Org. Biomol. Chem., 2003, 1, 772;
(d) J. Huang, K. Xu and T. Loh, Synthesis, 2003, 755; (e) J. L. Cohen,
A. Limon, R. Miledi and A. R. Chamberlin, Bioorg. Med. Chem.
Lett., 2006, 16, 2189; (f) W. R. F. Goundry, V. Lee and J. E. Baldwin,
Synlett, 2006, 2407; (g) J. L. Cohen and A. R. Chamberlin, Tetra-
hedron Lett., 2007, 48, 2533; (h) R. Fernandez de la Pradilla, N. Lwoff
and A. Viso, Tetrahedron Lett., 2007, 48, 8141; (i) C. L. Carroll and
A. R. Chamberlin, Tetrahedron Lett., 2011, 52, 3995.
1
The H NMR spectral data of 1ꢁ2HCl are highly dependent on
sample concentration, and are similar to that reported by Snider
and Hawryluk (0.005 M)7a and by Hatakeyama et al. (0.03 M).7c
While its optical rotation is known to be [a]D = ꢀ51 (c 0.06, H2O)
by Snider and Hawryluk7a and [a]D = +7.01 (c 0.53, H2O) by
23
Hatakeyama et al.,7f our value is [a]D23 = +7.01 (c 0.54, H2O).
In the case of (ꢀ)-dysiherbaine 1, the 1H NMR spectra are
almost identical with those previously published,7c,d,f its optical
rotation found by us, [a]D24 = ꢀ7.31 (c 0.38, H2O), is in good
agreement with the reported value, [a]D23 = ꢀ7.51 (c 0.52, H2O)
by Hatakeyama et al., (Scheme 4).7f
We report an efficient asymmetric total synthesis of (ꢀ)-dysi-
herbaine from the readily available chiral building block 4. The
synthesis has demonstrated the utility of the enantioselective
desymmetrization of the 2-substituted glycerol 3 to install a
quaternary chiral center, which is thought to guide further stereo-
selectivity in the formation of the bicyclic perhydro-furanopyran.
9 S. P. H. Mee, V. Lee and J. E. Baldwin, Angew. Chem., 2004, 116, 1152.
10 (a) B. Jung and S. H. Kang, Proc. Natl. Acad. Sci. U. S. A., 2007,
104, 1471; (b) B. Jung, M. S. Hong and S. H. Kang, Angew. Chem.,
Int. Ed., 2007, 46, 2616.
11 N. Kamiya, Y. Chikami and Y. Ishii, Synlett, 1990, 675.
12 G.-Q. Shi, X.-H. Huang and F. Hong, J. Org. Chem., 1996, 61, 3200.
13 M. J. Batchelor, R. J. Gillespie, J. M. C. Golec and C. J. R.
Hedgecock, Tetrahedron Lett., 1993, 34, 167.
14 K. Zhao and G. Stork, Tetrahedron Lett., 1989, 30, 2173.
15 J. D. White, P. R. Blakemore, N. J. Green, E. B. Hauser, M. A.
Holoboski, L. E. Koewn, C. S. N. Kolz and B. W. Phillips, J. Org.
Chem., 2002, 67, 7750.
16 S. H. Kang, J. H. Lee and S. B. Lee, Tetrahedron Lett., 1998, 39, 59.
17 Z. Zhang and G. Magnusson, J. Org. Chem., 1996, 61, 2394.
18 D. Yang, M.-K. Wong and Y.-C. Yip, J. Org. Chem., 1995, 60, 3887.
19 (a) M. Shibuya, M. Tomizawa, I. Suzuki and Y. Iwabuchi, J. Am.
Chem. Soc., 2006, 128, 8412; (b) M. Inai, T. Goto, T. Furuta,
T. Wakimoto and T. Kan, Tetrahedron: Asymmetry, 2008, 19, 2771.
20 O. Miyata, R. Iba, J. Hashimoto and T. Naito, Org. Biomol.
Chem., 2003, 1, 772.
Scheme 4 Preparation of dysiherbaine 1. (a) AZADO, PhI(OAc)2,
NaClO2, pH 6.2 phosphate buffer, MeCN, RT. (b) MeONH2ꢁHCl,
pyridine, 0 1C to RT, 88% (over 2 steps). (c) H2 (1 atm), Boc2O,
NaHCO3, Raney Ni, MeOH, RT. (d) NaH, MeI, DMF, 0 1C, 81%
(over 2 steps). (e) InCl3, wet MeCN, RT (96%). (f) AZADO,
PhI(OAc)2, NaClO2, pH 5.8 phosphate buffer, MeCN, RT, 99%.
(g) TMSCHN2, MeOH, PhH, RT, 100%. (h) 6 M HCl, 80 1C, 99%.
(i) 10 M aq NaOH, RT, then Amberlite, weakly acidic cation
exchanger, H form, 95%. AZADO = 2-azaadamantane N-oxyl.
c
This journal is The Royal Society of Chemistry 2012
Chem. Commun., 2012, 48, 6295–6297 6297